Bluejay Diagnostics, Inc. - 10-Q Filing
Bluejay Diagnostics filed its 10-Q for the quarter ended March 31, 2026, reporting a net loss of $1.92 million, or $1.95 per share, compared to a net loss of $1.86 million, or $13.46 per share, in the same period in 2025. The company's cash and cash equivalents decreased to $3.68 million from $5.16 million, and it remains focused on developing its Symphony diagnostic platform, which requires further capital to advance toward regulatory submission.
Tickers: $BJDX